Treatment effect of Ponatinib in Bangladesh

The Bangladeshi version of Ponatinib (Ponatinib) belongs to the category of generic drug production. Its pharmaceutical ingredients are basically the same as those of Ponatinib, but there are differences in price, manufacturer, specifications, etc. Ponatinib is a kinase inhibitor that inhibits the in vitro tyrosine kinase activity of ABL and T315I mutant ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR-ABL compared with controls. In PACE, the dose intensity-safety relationship showed that adverse reactions including hypertension, thrombocytopenia, pancreatitis, neutropenia, rash, and other adverse reactions were significantly increased in the dose range of 15 mg to 45 mg.